Managed Healthcare Executive
More CAR-T therapy treatments have been approved as the market continues to increase, but there are still some obstacles. Abhinav Deol, M.D., medical oncologist and member of the Bone Marrow & Stem Cell Transplant, Hematology Oncology and Multiple Myeloma and Amyloidosis Multidisciplinary Teams, gives comments on the current state of CAR-T, including the latest approvals and the cost of this new and promising cancer treatment.
Read the full article here.